Scholarlink

Background <p>Glucocorticoids (GC) are commonly administered during the febrile and hypotensive phases of hemorrhagic fever with renal syndrome (HFRS) to alleviate inflammation and capillary leakage. However, clinical dosing regimens show marked variability. This study aims to evaluate the clinical necessity of high-dose GC therapy during the acute phase of HFRS.</p> Methods <p>A retrospective study involving 807 HFRS patients admitted to two centers was conducted. Propensity score matching and multivariate logistic regression models were used to compare the effects of conventional-dose and high-dose GC on HFRS treatment outcomes and the risk of secondary infections.</p> Results <p>There were no significant differences in hospital stay, acute-phase fluid requirement, renal replacement rates, mechanical ventilation needs, severe hemorrhagic complications, or mortality between HFRS patients receiving conventional or high-dose GC. Among patients with a shock phase, the secondary infections rate was significantly higher with high-dose GC compared to conventional-dose (43.48% vs. 23.91%, <i>p</i> = 0.005). High-dose GC emerged as an independent risk factor for secondary infections (OR 2.88, 95%CI 1.41–5.88), while prophylactic antibiotics served as an independent protective factor (OR 0.29, 95%CI 0.13–0.65). In patients without a shock phase, no significant difference was observed in the effect of the two GC doses on secondary infections. However, GC therapy ≥ 4 days was an independent risk factor (OR 2.54, 95%CI 1.21–5.37).</p> Conclusions <p>High-dose GC show no superiority over conventional-dose GC on hospital stay, acute-phase fluid requirement, renal replacement rates, mechanical ventilation needs, severe hemorrhagic complications, or mortality. High-dose GC may increase secondary infections in HFRS patients with a shock phase. GC therapy ≥ 4 days may also increase secondary infections in patients without a shock phase.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of clinical efficacy and secondary infections between conventional-dose and high-dose glucocorticoid in hemorrhagic fever with renal syndrome: a dual-center retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月30日

查看全文
  • Denghui Yu,
  • Jiayi Zhan,
  • Hong Du,
  • Pingping Zhu,
  • Haifeng Hu,
  • Hongkai Xu,
  • Ludan Zhang,
  • Fei Hu,
  • Zhanhu Bi,
  • Xiaofei Yang,
  • Yanping Li,
  • Jianqi Lian

摘要

Background

Glucocorticoids (GC) are commonly administered during the febrile and hypotensive phases of hemorrhagic fever with renal syndrome (HFRS) to alleviate inflammation and capillary leakage. However, clinical dosing regimens show marked variability. This study aims to evaluate the clinical necessity of high-dose GC therapy during the acute phase of HFRS.

Methods

A retrospective study involving 807 HFRS patients admitted to two centers was conducted. Propensity score matching and multivariate logistic regression models were used to compare the effects of conventional-dose and high-dose GC on HFRS treatment outcomes and the risk of secondary infections.

Results

There were no significant differences in hospital stay, acute-phase fluid requirement, renal replacement rates, mechanical ventilation needs, severe hemorrhagic complications, or mortality between HFRS patients receiving conventional or high-dose GC. Among patients with a shock phase, the secondary infections rate was significantly higher with high-dose GC compared to conventional-dose (43.48% vs. 23.91%, p = 0.005). High-dose GC emerged as an independent risk factor for secondary infections (OR 2.88, 95%CI 1.41–5.88), while prophylactic antibiotics served as an independent protective factor (OR 0.29, 95%CI 0.13–0.65). In patients without a shock phase, no significant difference was observed in the effect of the two GC doses on secondary infections. However, GC therapy ≥ 4 days was an independent risk factor (OR 2.54, 95%CI 1.21–5.37).

Conclusions

High-dose GC show no superiority over conventional-dose GC on hospital stay, acute-phase fluid requirement, renal replacement rates, mechanical ventilation needs, severe hemorrhagic complications, or mortality. High-dose GC may increase secondary infections in HFRS patients with a shock phase. GC therapy ≥ 4 days may also increase secondary infections in patients without a shock phase.